Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

Blood (2022) 140 (Supplement 1): 13264–13266.

https://doi.org/10.1182/blood-2022-159637

Published: 2022

Journal Articles

Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment

Rakesh Popat, Sikander Ailawadhi, David Kleinman, Sue Perera, Boris Gorsh, Caitlin Thomas, Sarah Mulnick, Alicia O'Neill, Melissa Ross, Prani Paka, Maya Hanna, Alexa Molinari, Shivaranjani Naine, Heather Gelhorn

Blood (2022) 140 (Supplement 1): 7211–7213.

https://doi.org/10.1182/blood-2022-164795

Published: 2022

Journal Articles

Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

Malin Hultcrantz, David Kleinman, Ravi Vij, Fernando Escalante, Nirali Kotowsky, Jacopo Bitetti, Christine Mackay, Natalie Boytsov, Leena Camadoo-O'Byrne, Guillaume Germain, Mei Sheng Duh, François Laliberté, Malena Mahendran, Ana Urosevic, Hans C. Lee

Blood (2022) 140 (Supplement 1): 10124–10126.

https://doi.org/10.1182/blood-2022-164929

Published: 2022

Journal Articles

Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14

Malin Hultcrantz, David Kleinman, Pavandeep Ghataorhe, Astrid McKeown, Wei He, Thomas Ling, Roxanne C Jewell, Joseph Brunner, Julie Byrne, Laurie Eliason, Emma Scott, Joanna Opalinska

Blood (2021) 138 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2021-152224

Published: 2021